# Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Study · id `cardio:ct-nct02296190` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02296190](<https://clinicaltrials.gov/study/NCT02296190>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02296190

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

## Technical summary

Registry record NCT02296190. Randomized; double masking; primary purpose treatment. Start 2015-03-27 (registry gives no type); primary completion 2016-12 (actual). Results posted on 2020-12-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 199 participants (enrolled count; ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Start date: 2015-03-27 (registry gives no type) (ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Results first posted: 2020-12-30 (ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02296190, source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02296190-2020-12-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
- Acronym: NODE-1
- Condition: Paroxysmal Supraventricular Tachycardia (PSVT)
- Intervention (Drug): Etripamil
- Intervention (Drug): Placebo
- Lead sponsor: Milestone Pharmaceuticals Inc.
- Lead sponsor class: OTHER
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Milestone Pharmaceuticals Inc. (`cardio:org-milestone-pharmaceuticals-inc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm (`cardio:pubmed-30049309`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 34a01edbabaf77d405d820a3226171679993dc6168d2358556ebcab234ac2264
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
